Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin combined with insulin pump for type 2 diabetes mellitus
ChiCTR1800018292Phase 4Recruiting
- Sponsor
- Tianjin TEDA International Cardiovascular Hospital
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of dapagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Tianjin TEDA International Cardiovascular Hospital. Primary endpoint: Glycated hemoglobin. Started Mar 2017; status: recruiting.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR1800018292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800018292.